ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Interim Dean Henney Looking for Cancer Center Director; Shingleton Gets James Ewing Award

June 10, 1988

DCE Board Okays Concepts For More Than $6 Million

March 13, 1987

Lung Screening Study Ties Up Advisors, Board Sends It Back To NCI For Revision.

June 29, 2001

Rosenberg’s Adoptive Immunotherapy Update

December 6, 1985

House Subcommittee voted $1.011 Billion For NCU 1981 Fiscal Year Budget In Closed Door Meeting

August 8, 1980

ASCO Awards Contract For D.C Office

January 12, 1990